Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

bioMérieux S.A.. (5/28/14). "Press Release: The General Shareholders’ Meeting of bioMérieux Approves the Appointment of Two New Independent Directors". Marcy l’Étoile.

Organisation Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 molecular diagnostics
Persons Person Bélingard, Jean-Luc (Mérieux 201101– Président Directeur Général before Ipsen CEO + Pierre Fabre + Roche Diagnostics)
  Person 2 Mérieux, Alain (bioMérieux 200702 President + Founder)

The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent directors, Agnès Lemarchand and Philippe Gillet.

Agnès Lemarchand and Philippe Gillet were appointed to replace Georges Hibon and Michel Angé, who did not wish to renew their terms of office as directors. The Board of Directors thanked them for the important role they have played in the Company's development for many years.

The new Board of Directors of bioMérieux will thus be comprised of Jean-Luc Belingard (Chairman), Alain Mérieux, Alexandre Mérieux, Philippe Archinard, and five independent directors: Harold Boël, Philippe Gillet, Marie-Hélène Habert, Agnès Lemarchand and Michele Palladino.

The General Meeting of Shareholders moreover approved the appointment of Michel Angé and Henri Thomasson as non-voting directors (censeurs). Michel Angé was previously a director, and Henri Thomasson was formerly Chief Financial Officer of bioMérieux.

Agnès Lemarchand: Background

Agnès Lemarchand, a French national, was born in Marquette-lez-Lille on December 29, 1954. She is a graduate of ENSCP (Ecole Nationale Supérieure de Chimie de Paris), Massachusetts Institute of Technology, and INSEAD. She has spent her career in industry. She has served as Chief Executive Officer of Industrie Biologique Française (a joint venture between the Rhône-Poulenc group and Institut Mérieux), Chairman and Chief Executive Officer of Prodical (a subsidiary of the Ciments Français group), and Chairman and Chief Executive Officer of the Lafarge group's lime business.

In 2005, together with the key employees, she took over the Lafarge UK lime business and founded Steetley Dolomite Ltd (UK), where she serves as Chairman. In addition, she is a director on the Saint-Gobain Board of Directors and sits on the CGG Board of Directors. She is also a member of the supervisory boards of both Areva and Siclae (where she represents Bpifrance). She is a member of the steering committee of the "34 Plans de la Nouvelle France Industrielle".

Philippe Gillet: Background

Philippe Gillet, a French national, was born in Strasbourg on January 26, 1956, and lives in Switzerland. He is a graduate of l'Ecole Normale Supérieure de Paris and earned a PhD in geophysics and geochemistry as well as a State doctorate in geosciences. He was a professor of geophysics at the University of Rennes prior to becoming Director of l'Ecole Normale Supérieure de Lyon, where he was also a professor of Earth Sciences. In addition, from May 2007 to April 2010 he served as Chief of Staff for the French Minister of Higher Education and Research. He subsequently joined l'Ecole Polytechnique Fédérale of Lausanne, where he serves as Vice President for Academic Affairs. At the same time, he continues his teaching activities as a professor and directs the Earth and Planetary Sciences Laboratory.


Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, bioMérieux's revenues reached €1,588 million with 87% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Corporate website: and investor website:


Investor Relations
Isabelle Tongio
Tel: +33 4 78 87 22 37

Media Relations
Aurore Sergeant Tel: +33 4 78 87 54 75

Image Sept
Laurence Heilbronn
Tel: +33 1 53 70 74 64
Claire Doligez
Tel: +33 1 53 70 74 48

Record changed: 2016-03-20


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

More documents for Mérieux (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top